Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04753697




Registration number
NCT04753697
Ethics application status
Date submitted
5/02/2021
Date registered
15/02/2021
Date last updated
30/01/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Scientific title
A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Active Eosinophilic Esophagitis.
Secondary ID [1] 0 0
U1111-1263-4351
Secondary ID [2] 0 0
CC-93538-EE-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Eosinophilic Esophagitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Inflammatory and Immune System 0 0 0 0
Allergies

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CC-93538
Other interventions - Placebo

Experimental: Administration of CC-93538 - CC-93538 360 mg Subcutaneously (SC) once weekly for 24 weeks followed by CC-93538 360 mg SC once weekly for 24 weeks

Experimental: Administration of CC-93538 and Placebo - CC-93538 360 mg SC once weekly for 24 weeks followed by CC-93538 360 mg SC once every other week for 24 weeks.
During the Maintenance Phase, matching placebo will be administered once every other week on alternate weeks to maintain the blind.

Placebo Comparator: Administration of Placebo - Matching placebo SC once weekly for 24 weeks followed by matching placebo SC once weekly for 24 weeks


Treatment: Drugs: CC-93538
Subcutaneous

Other interventions: Placebo
Subcutaneous
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in DD Clinical Response
Timepoint [1] 0 0
At week 24
Primary outcome [2] 0 0
Eosinophil Histologic Response (= 6/hpf)
Timepoint [2] 0 0
At week 24
Secondary outcome [1] 0 0
Eosinophil Histologic Response (< 15/hpf)
Timepoint [1] 0 0
At week 24
Secondary outcome [2] 0 0
EoE Endoscopic Reference Score (EREFS)
Timepoint [2] 0 0
At week 24
Secondary outcome [3] 0 0
EoEHSS Grade Score
Timepoint [3] 0 0
At week 24
Secondary outcome [4] 0 0
EoEHSS Stage Score
Timepoint [4] 0 0
At week 24
Secondary outcome [5] 0 0
mDSD Composite Score
Timepoint [5] 0 0
At week 24
Secondary outcome [6] 0 0
DD Clinical Responder Definition
Timepoint [6] 0 0
At week 24
Secondary outcome [7] 0 0
Kinetics and Onset of Clinical Response_DD
Timepoint [7] 0 0
Through week 24
Secondary outcome [8] 0 0
Kinetics and Onset of Clinical Response_mDSD
Timepoint [8] 0 0
Through week 24
Secondary outcome [9] 0 0
Time to Event _EoE Flare
Timepoint [9] 0 0
Through week 24
Secondary outcome [10] 0 0
Time to Event_Rescue Therapy
Timepoint [10] 0 0
Through Week 24
Secondary outcome [11] 0 0
Proportion of Participants with Event-EoE Flare
Timepoint [11] 0 0
Through week 24
Secondary outcome [12] 0 0
Proportion of Participants with Event_Rescue Therapy
Timepoint [12] 0 0
Through week 24
Secondary outcome [13] 0 0
Incidence of Adverse Events (AEs)
Timepoint [13] 0 0
Through week 48
Secondary outcome [14] 0 0
Assessment of Immunogenicity through measurement of serum concentrations of anti-drug antibodies to CC-93538
Timepoint [14] 0 0
Through week 48
Secondary outcome [15] 0 0
Pharmacokinetics- Ctrough
Timepoint [15] 0 0
Through week 24
Secondary outcome [16] 0 0
Change in DD Clinical Response
Timepoint [16] 0 0
At week 48
Secondary outcome [17] 0 0
Eosinophil Histologic Response (= 6/hpf)
Timepoint [17] 0 0
At week 48
Secondary outcome [18] 0 0
Eosinophil Histologic Response (< 15/hpf)
Timepoint [18] 0 0
At week 48
Secondary outcome [19] 0 0
Mean change in EREFS
Timepoint [19] 0 0
At week 48
Secondary outcome [20] 0 0
EoEHSS Grade Score
Timepoint [20] 0 0
At week 48
Secondary outcome [21] 0 0
EoEHSS Stage Score
Timepoint [21] 0 0
At week 48
Secondary outcome [22] 0 0
mDSD Composite Score
Timepoint [22] 0 0
At week 48
Secondary outcome [23] 0 0
Time to event_EoE Flare (Induction and Maintenance Phase)
Timepoint [23] 0 0
Through week 48
Secondary outcome [24] 0 0
Time to event_rescue therapy (Induction and Maintenance Phase)
Timepoint [24] 0 0
Through week 48
Secondary outcome [25] 0 0
Proportion of Participants with Event_EoE Flare (Induction and Maintenance Phase)
Timepoint [25] 0 0
Through week 48
Secondary outcome [26] 0 0
Proportion of participants with event rescue therapy (Induction and Maintenance Phases)
Timepoint [26] 0 0
Through week 48
Secondary outcome [27] 0 0
Pharmacokinetics-Ctrough
Timepoint [27] 0 0
Through week 48

Eligibility
Key inclusion criteria
Participants must satisfy the following criteria to be enrolled in the study:

1. Male or female patients aged = 12 and = 75 years, with a body weight of > 40 kg.

2. Histologic evidence of eosinophilic esophagitis, defined as a peak count of = 15
eosinophils/high-power field at 2 levels of the esophagus.

3 Participant-reported history of 4 or more Dysphagia Days within 2 consecutive weeks prior
to end of screening.

4. Lack of complete response to an adequate trial of proton pump inhibitor (8 weeks).
Participants on a proton pump inhibitor must have been on a stable dose for at least 4
weeks prior to first Screening Visit and agree to continue the same dose throughout the
study.

5. Participants currently receiving inhaled corticosteroids, leukotriene receptor
antagonists, or mast cell stabilizers for indications other than EoE, or medium potency
topical corticosteroids for dermatologic conditions, must maintain stable doses for at
least 4 weeks prior to the first Screening Visit and throughout the duration of the study.

6. Participants must agree to maintain a stable diet (including any food elimination diet
for the treatment of food allergy or eosinophilic esophagitis) and not introduce any
changes in their diet from the first Screening Visit to the end of the study.

7. Females of childbearing potential must have 2 negative pregnancy tests as verified by
the Investigator prior to starting study therapy and agree to practice a highly effective
method of contraception until 5 months after the last dose.
Minimum age
12 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
The presence of any of the following will exclude a participant from enrollment:

1. Clinical or endoscopic evidence of other diseases that may affect the histologic,
endoscopic, and clinical symptom evaluation for this study.

2. Other gastrointestinal disorders such as active Helicobacter pylori infection,
esophageal varices, gastritis, colitis, celiac disease, Mendelian disorder associated
with eosinophilic esophagitis, liver function impairment, or a known hereditary
fructose intolerance.

3. Evidence of a severe endoscopic structural abnormality in the esophagus.

4. Esophageal dilation for symptom relief within 8 weeks prior to first Screening Visit
or during the Screening Period, or if esophageal dilation is anticipated within 48
weeks of dosing during the study.

5. Evidence of immunosuppression, or of having received systemic immunosuppressive or
immunomodulating drugs within 5 drug half-lives prior to the first Screening Visit.

6. Treatment with a high potency topical corticosteroid for dermatologic use, or a
systemic corticosteroid within 8 weeks of the first Screening Visit.

7. Treatment with a swallowed topical corticosteroid, leukotriene receptor antagonist, or
mast cell stabilizer for EoE, within 4 weeks of the first Screening Visit.

8. Treatment with oral or sublingual immunotherapy within 6 months of the first Screening
Visit (any use will be prohibited during the study). Subcutaneous immunotherapy may be
allowed if on stable doses for at least 3 months prior to the first Screening Visit
and during the study.

9. Actively successful dietary modification adherence (e.g. food elimination diet),
resulting in a complete response to EoE.

10. Prior treatment with CC-93538 during a Phase 1 or 2 clinical study.

11. Receipt of a live attenuated vaccine within 4 weeks of the first Screening Visit.

12. Any disease that would affect the conduct of the protocol or interpretation of the
study results, or would put a patient at risk by participating in the study (e.g.
severe uncontrolled asthma, infection causing eosinophilia, hypereosinophilic
syndrome, or cardiovascular condition, or neurologic disorder or psychiatric illness
that compromises the Participant's ability to accurately document symptoms of
eosinophilic esophagitis).

13. Active or ongoing infections including parasitic/helminthic, hepatitis, tuberculosis,
or human immunodeficiency virus.

14. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks
of the first Screening Visit.

15. Females who are pregnant or lactating.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/02/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
2/10/2024
Actual
Sample size
Target
Accrual to date
Final
430
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 548 - Concord
Recruitment hospital [2] 0 0
Local Institution - 554 - Liverpool
Recruitment hospital [3] 0 0
Local Institution - 540 - Westmead
Recruitment hospital [4] 0 0
Local Institution - 546 - Maroorchydore
Recruitment hospital [5] 0 0
Local Institution - 550 - South Brisbane
Recruitment hospital [6] 0 0
Local Institution - 542 - Woolloongabba
Recruitment hospital [7] 0 0
Local Institution - 552 - Adelaide
Recruitment hospital [8] 0 0
Local Institution - 545 - Elizabeth Vale
Recruitment hospital [9] 0 0
Local Institution - 553 - Clayton
Recruitment hospital [10] 0 0
Local Institution - 543 - Footscray
Recruitment hospital [11] 0 0
Local Institution - 539 - Melbourne
Recruitment hospital [12] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [13] 0 0
Local Institution - 538 - Fitzroy
Recruitment hospital [14] 0 0
Local Institution - 547 - Western Australia
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4558 - Maroorchydore
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [7] 0 0
5000 - Adelaide
Recruitment postcode(s) [8] 0 0
05112 - Elizabeth Vale
Recruitment postcode(s) [9] 0 0
3168 - Clayton
Recruitment postcode(s) [10] 0 0
3011 - Footscray
Recruitment postcode(s) [11] 0 0
3004 - Melbourne
Recruitment postcode(s) [12] 0 0
6150 - Murdoch
Recruitment postcode(s) [13] 0 0
3065 - Fitzroy
Recruitment postcode(s) [14] 0 0
6056 - Western Australia
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Iowa
Country [13] 0 0
United States of America
State/province [13] 0 0
Kansas
Country [14] 0 0
United States of America
State/province [14] 0 0
Kentucky
Country [15] 0 0
United States of America
State/province [15] 0 0
Louisiana
Country [16] 0 0
United States of America
State/province [16] 0 0
Maryland
Country [17] 0 0
United States of America
State/province [17] 0 0
Massachusetts
Country [18] 0 0
United States of America
State/province [18] 0 0
Michigan
Country [19] 0 0
United States of America
State/province [19] 0 0
Minnesota
Country [20] 0 0
United States of America
State/province [20] 0 0
Mississippi
Country [21] 0 0
United States of America
State/province [21] 0 0
Missouri
Country [22] 0 0
United States of America
State/province [22] 0 0
Nebraska
Country [23] 0 0
United States of America
State/province [23] 0 0
New Hampshire
Country [24] 0 0
United States of America
State/province [24] 0 0
New Mexico
Country [25] 0 0
United States of America
State/province [25] 0 0
New York
Country [26] 0 0
United States of America
State/province [26] 0 0
North Carolina
Country [27] 0 0
United States of America
State/province [27] 0 0
Ohio
Country [28] 0 0
United States of America
State/province [28] 0 0
Oklahoma
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
Rhode Island
Country [31] 0 0
United States of America
State/province [31] 0 0
South Carolina
Country [32] 0 0
United States of America
State/province [32] 0 0
Tennessee
Country [33] 0 0
United States of America
State/province [33] 0 0
Texas
Country [34] 0 0
United States of America
State/province [34] 0 0
Utah
Country [35] 0 0
United States of America
State/province [35] 0 0
Virginia
Country [36] 0 0
United States of America
State/province [36] 0 0
Washington
Country [37] 0 0
United States of America
State/province [37] 0 0
Wisconsin
Country [38] 0 0
United States of America
State/province [38] 0 0
Wyoming
Country [39] 0 0
Argentina
State/province [39] 0 0
Buenos Aires
Country [40] 0 0
Argentina
State/province [40] 0 0
Mar Del Plata
Country [41] 0 0
Argentina
State/province [41] 0 0
Quilmes
Country [42] 0 0
Austria
State/province [42] 0 0
Burgenland
Country [43] 0 0
Austria
State/province [43] 0 0
Graz
Country [44] 0 0
Austria
State/province [44] 0 0
Linz
Country [45] 0 0
Belgium
State/province [45] 0 0
Brussels
Country [46] 0 0
Belgium
State/province [46] 0 0
Kortrijk
Country [47] 0 0
Belgium
State/province [47] 0 0
Leuven
Country [48] 0 0
Belgium
State/province [48] 0 0
West-Vlaanderen
Country [49] 0 0
Canada
State/province [49] 0 0
Alberta
Country [50] 0 0
Canada
State/province [50] 0 0
British Columbia
Country [51] 0 0
Canada
State/province [51] 0 0
Ontario
Country [52] 0 0
Germany
State/province [52] 0 0
Bayern
Country [53] 0 0
Germany
State/province [53] 0 0
Brandenburg an der Havel
Country [54] 0 0
Germany
State/province [54] 0 0
Frankfurt am Main
Country [55] 0 0
Germany
State/province [55] 0 0
Hamburg
Country [56] 0 0
Germany
State/province [56] 0 0
Leipzig
Country [57] 0 0
Germany
State/province [57] 0 0
Munchen
Country [58] 0 0
Germany
State/province [58] 0 0
München
Country [59] 0 0
Israel
State/province [59] 0 0
Haifa
Country [60] 0 0
Israel
State/province [60] 0 0
Holon
Country [61] 0 0
Israel
State/province [61] 0 0
Jerusalem
Country [62] 0 0
Israel
State/province [62] 0 0
Tel Aviv
Country [63] 0 0
Israel
State/province [63] 0 0
Zerifin
Country [64] 0 0
Italy
State/province [64] 0 0
Genova
Country [65] 0 0
Italy
State/province [65] 0 0
Milano
Country [66] 0 0
Italy
State/province [66] 0 0
Padova
Country [67] 0 0
Italy
State/province [67] 0 0
Pisa
Country [68] 0 0
Italy
State/province [68] 0 0
Rome
Country [69] 0 0
Japan
State/province [69] 0 0
Hyogo
Country [70] 0 0
Japan
State/province [70] 0 0
Tokyo
Country [71] 0 0
Japan
State/province [71] 0 0
Akita-shi
Country [72] 0 0
Japan
State/province [72] 0 0
Isehara City, Kanagawa
Country [73] 0 0
Japan
State/province [73] 0 0
Kobe
Country [74] 0 0
Japan
State/province [74] 0 0
Maebashi
Country [75] 0 0
Japan
State/province [75] 0 0
Nagoya
Country [76] 0 0
Japan
State/province [76] 0 0
Niigata-shi
Country [77] 0 0
Japan
State/province [77] 0 0
Okayama-Shi
Country [78] 0 0
Japan
State/province [78] 0 0
Osaka
Country [79] 0 0
Japan
State/province [79] 0 0
Shibukawa
Country [80] 0 0
Japan
State/province [80] 0 0
Shinjuku-Ku
Country [81] 0 0
Japan
State/province [81] 0 0
Toyoake
Country [82] 0 0
Japan
State/province [82] 0 0
Yamagata
Country [83] 0 0
Poland
State/province [83] 0 0
Bydgoszcz
Country [84] 0 0
Poland
State/province [84] 0 0
Czestochowa
Country [85] 0 0
Poland
State/province [85] 0 0
Gdansk
Country [86] 0 0
Poland
State/province [86] 0 0
Katowice
Country [87] 0 0
Poland
State/province [87] 0 0
Lódz
Country [88] 0 0
Poland
State/province [88] 0 0
Warsaw
Country [89] 0 0
Poland
State/province [89] 0 0
Warszawa
Country [90] 0 0
Poland
State/province [90] 0 0
Wroclaw
Country [91] 0 0
Portugal
State/province [91] 0 0
Lisboa
Country [92] 0 0
Portugal
State/province [92] 0 0
Porto
Country [93] 0 0
Spain
State/province [93] 0 0
Barcelona
Country [94] 0 0
Spain
State/province [94] 0 0
Cordoba
Country [95] 0 0
Spain
State/province [95] 0 0
Madrid
Country [96] 0 0
Spain
State/province [96] 0 0
Marbella
Country [97] 0 0
Spain
State/province [97] 0 0
Sevilla
Country [98] 0 0
Switzerland
State/province [98] 0 0
Lausanne
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Belfast Northern Ireland
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Birmingham
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Cardiff
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Chorley
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Hexam
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Liverpool
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Manchester
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Celgene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind,
placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC-
93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study
will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase.

Participants will be randomized at the beginning of the study into 3 treatment arms:

- Placebo for Induction and Maintenance

- CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once
every other week for Maintenance

- CC-93538 360 mg SC once weekly for Induction and Maintenance
Trial website
https://clinicaltrials.gov/ct2/show/NCT04753697
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04753697